SeekingAlpha · Mar 3, 2026
OraSure Technologies, Inc. 2025 Q4 - Results - Earnings Call Presentation
2026-03-03. The following slide deck was published by OraSure Technologies, Inc.

NASDAQ · OSUR
Healthcare · Medical - Instruments & Supplies
$3.25
Up+$0.02 (+0.62%)
Updated Sep 12, 2026, 5:18 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
OSUR closed at $3.25 after 20 trading sessions, down 15.36% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $3.27 | $3.28 | $3.195 | $3.25 | 467.28K |
| Sep 10, 2026 | $3.33 | $3.33 | $3.145 | $3.23 | 1.01M |
| Sep 9, 2026 | $3.35 | $3.39 | $3.33 | $3.36 | 413.08K |
| Sep 8, 2026 | $3.46 | $3.48 | $3.375 | $3.39 | 354.25K |
| Sep 4, 2026 | $3.55 | $3.635 | $3.465 | $3.48 | 304.67K |
| Sep 3, 2026 | $3.64 | $3.65 | $3.52 | $3.58 | 211.26K |
| Sep 2, 2026 | $3.53 | $3.68 | $3.53 | $3.61 | 345.28K |
| Sep 1, 2026 | $3.59 | $3.655 | $3.52 | $3.53 | 329K |
| Aug 31, 2026 | $3.61 | $3.65 | $3.54 | $3.59 | 326.1K |
| Aug 28, 2026 | $3.70 | $3.73 | $3.58 | $3.60 | 249.96K |
| Aug 27, 2026 | $3.74 | $3.74 | $3.65 | $3.69 | 255.28K |
| Aug 26, 2026 | $3.77 | $3.79 | $3.69 | $3.71 | 249.98K |
| Aug 25, 2026 | $3.83 | $3.835 | $3.75 | $3.78 | 275.2K |
| Aug 24, 2026 | $3.88 | $3.93 | $3.765 | $3.82 | 348.09K |
| Aug 21, 2026 | $3.78 | $3.90 | $3.72 | $3.88 | 769.34K |
| Aug 20, 2026 | $3.67 | $3.79 | $3.65 | $3.74 | 647.42K |
| Aug 19, 2026 | $3.79 | $3.855 | $3.70 | $3.70 | 419.15K |
| Aug 18, 2026 | $3.81 | $3.84 | $3.72 | $3.75 | 459.75K |
| Aug 17, 2026 | $3.84 | $3.856 | $3.765 | $3.81 | 357.77K |
| Aug 14, 2026 | $4.02 | $4.02 | $3.835 | $3.84 | 582.45K |
The latest Smart Investors Daily articles mentioning OSUR.
OSUR research
Company profile and research snapshot.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 12, 2025 | Stephens & Co. | Equal-Weight | — |
| May 19, 2025 | Evercore ISI Group | In-Line | — |
| Aug 7, 2024 | Evercore ISI Group | In-Line | — |
| Jul 2, 2024 | Evercore ISI Group | In-Line | — |
| May 13, 2024 | JP Morgan | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Mar 3, 2026
2026-03-03. The following slide deck was published by OraSure Technologies, Inc.
Benzinga · Feb 26, 2026
ChartMill · Feb 26, 2026
OraSure posts mixed Q4 results with revenue beat but deeper core decline. Focus shifts to 2026 growth from new pipeline products like CT/NG self-test.
SeekingAlpha · Feb 25, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning OSUR.